Table 3 |
|||
|
Stratification by covariates |
|||
|
Variable |
Number of studies |
Significant % reduction in VRE acquisition |
Fisher's exact test comparing strata |
|
|
|||
|
Type of intervention |
NS1 |
||
|
Vancomycin reduction alone |
6 |
2 |
|
|
Vancomycin plus other interventions |
7 |
5 |
|
|
Site-based2 |
(p = 0.029, FET2) |
||
|
Ward alone |
7 |
6 |
|
|
Hospital-wide |
6 |
1 |
|
|
VRE acquisition occurrence3 |
NS |
||
|
Outbreak only |
2 |
2 |
|
|
Endemic (with or without outbreak) |
9 |
3 |
|
|
Study design |
NS |
||
|
A1 |
5 |
3 |
|
|
A1* |
4 |
4 |
|
|
A2 † |
5 |
2 |
|
|
Duration of intervention |
NS |
||
|
≤ 6 months |
4 |
3 |
|
|
> 6 months |
9 |
4 |
|
|
|
|||
|
1 NS = not significant result of Fisher's exact test comparing strata 2 Stratification by severity of illness yields identical results to the site-based stratification: "ward alone" and "high severity of illness" are identical strata; "hospital wide" and moderate severity of illness" are identical strata 3Excluded Rubin et al. (initial cases) and Fridkin et al. (multi-cite, outbreak/endemic status not reported) A1 = 1-group pretest-posttest design; A2 = 1-group pretest-posttest design that uses a double pre-test (for a complete description of hierarchy of quasi-experimental design studies, see Harris et al.), * Category A1 with multiple post-tests; † Category A2 with multiple post-tests |
|||
|
de Bruin and Riley BMC Infectious Diseases 2007 7:24 doi:10.1186/1471-2334-7-24 |
|||